Effects of paravertebral nerve block combined with transcranial direct current stimulation on pain and mood in patients with postherpetic neuralgia

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200060187

Enrollment

Unknown

Registered

2022-05-21

Start date

2022-05-10

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postherpetic neuralgia

Interventions

Experimental group:Transcranial direct current stimulation is used

Control group:The electrode of the instrument is placed in the corresponding position, but no stimulation is given

Eligibility

Sex/Gender

All

Age

50 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. In accordance with the Chinese Expert Consensus on the Diagnosis and Treatment of postherpetic neuralgia 2016 Diagnosis of postherpetic neuralgia: herpes zoster (HZ) rash healing pain lasting for more than 1 month; 2. Aged 50-80 years; 3. The distribution area of protoherpes is located in the distribution area of C5-S1 nerve; 4. Basic drug therapy, NRS score at baseline >=4; 5. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Contraindications for tDCS: such as the use of implantable electronic devices (cardiac pacemakers, etc.), intracranial metal implants, epilepsy, etc.; 2. Coagulation dysfunction; 3. Severe cardiopulmonary dysfunction or liver and kidney insufficiency; 4. There is skin damage or local infection at the puncture site and electrical stimulation site; 5. Patients who are allergic to the drugs used for treatment or are not suitable for nerve block; 6. Can not cooperate with treatment and evaluation, such as Parkinson's disease, schizophrenia, epilepsy, dementia and other serious cognitive dysfunction; 7. Implantation of pain relief devices, such as spinal nerve stimulators; 8. Take antidepressants or sedatives; 9. Other neuropathic pain, such as diabetic peripheral neuropathy; 10. Participating in or participating in other clinical trials within the previous 12 weeks.

Design outcomes

Primary

Measure	Time frame
Numeric rating scale score for pain;	—

Secondary

Measure	Time frame
Brief pain assessment scale;The 7-item generalized anxiety disorder scale (GAD-7);Patient health questionnaire-9;Analgesic drug use;Treatment efficiency;Rescue analgesic use;	—

Countries

China

Contacts

Public ContactShen Wen

1084452435@qq.com+86 13913452217

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026